AI Article Synopsis
- The text discusses a slow-growing nontuberculous mycobacterium (NTM) that causes less than 0.2% of NTM infections and was first identified in 1972.
- Infections typically present similarly to pulmonary tuberculosis but can also occur outside the lungs, primarily affecting those with pre-existing lung issues or weakened immune systems.
- A specific case is highlighted involving a 23-year-old woman with a history of pneumonia and Crohn's disease, who developed an NTM infection while undergoing treatment with adalimumab, a medication that increases susceptibility to serious infections.
Article Abstract
is a slow-growing nontuberculous mycobacterium (NTM). It was first described in 1972 and is responsible for less than 0.2% of all NTM infections. The most common presentation resembles pulmonary tuberculosis, but it may also present as an extrapulmonary disease. It primarily affects individuals with underlying lung disease or immunocompromising conditions. The increasing use of tumor necrosis factor-alpha inhibitors, such as adalimumab, is associated with an increased risk of serious infections. We report a case of infection in a 23-year-old woman with a history of childhood pneumonia and Crohn's disease on adalimumab.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10826269 | PMC |
| http://dx.doi.org/10.7759/cureus.51388 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Epidemiology and clinical outcomes in skin and soft tissue nontuberculous mycobacteria infections: A retrospective study.
J Infect Public Health
January 2025
Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. Electronic address:
Background: Nontuberculous mycobacteria (NTM) are emerging pathogens responsible for increasing skin and soft tissue infections (SSTIs) globally. However, the diagnosis and treatment of NTM SSTIs face significant challenges due to the lack of standardized guidelines. This study reviewed the clinical characteristics, diagnostic challenges, and treatment outcomes of NTM SSTIs in a large cohort from a tertiary referral center in Beijing, China.
View Article and Find Full Text PDFDisseminated infection in an immunocompromised adult: An uncommon etiology of skin infection.
IDCases
December 2024
Department of Medicine, Mary Washington Healthcare, Fredericksburg, VA, USA.
is a rapidly growing nontuberculous mycobacterium (NTM) that is ubiquitous in the environment and is associated with skin and soft tissue infections (1). Because is an opportunistic infection, it can present as skin abscess, cellulitis, osteomyelitis, pulmonary infection or disseminated infections, particularly in individuals with compromised immune systems or underlying lung conditions such as cystic fibrosis or bronchiectasis. is one of the most pathogenic rapidly growing mycobacteria (RGM).
View Article and Find Full Text PDFMixed nontuberculous mycobacteria in an immunocompromised patient with probable progressive multifocal leukoencephalopathy.
IJID Reg
March 2025
SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Human Genetics, Stellenbosch University, Cape Town, South Africa.
Objectives: Nontuberculous mycobacteria (NTM) are increasingly recognized opportunistic pathogens found ubiquitously in the environment. The presence of multiple NTM species at the site of disease complicates diagnosis and treatment.
Case And Management: A 40-year-old patient who tested positive for HIV, with an absolute clusters of differentiation 4+ T-cell count of 3 cells/µl and cryptococcaemia, presented with hemoptysis, productive cough, and weight loss.
In vitro activity of omadacycline against geographically diverse rapidly growing nontuberculous mycobacteria (NTM) clinical isolates.
Diagn Microbiol Infect Dis
December 2024
Department of Medical Microbiology, Radboudumc Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.
Nontuberculous mycobacteria (NTM) are emerging opportunistic pathogens with limited treatment options due to resistance to multiple antibiotic classes. This study aimed to evaluate the in vitro activity of omadacycline and comparator antibiotics against rapidly growing mycobacteria (RGM) clinical isolates. Minimum inhibitory concentration (MIC) evaluation of RGM clinical isolates was performed by two independent laboratories (EU and Japan).
View Article and Find Full Text PDFBackground: Due to its increasing prevalence and suboptimal treatment, non-tuberculous mycobacterial (NTM) infection is an emerging problem in patients with cystic fibrosis (CF). Detailed description of regional NTM prevalence and distribution, and identification of predictors of NTM acquisition in CF are essential to optimise treatment and surveillance guidelines.
Methods: A retrospective, multi-center analysis was conducted between the years 2020 and 2022 on data from 232 adult patients registered in the Hungarian CF Registry in 2022.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!